Google settles YouTube children's privacy lawsuit
Google will pay US$30 million to settle a lawsuit claiming it violated the privacy of children using YouTube by collecting their personal information without parental consent, and using it to send targeted ads.
A preliminary settlement of the proposed class action was filed on Monday night in San Jose, California, federal court, and requires approval by U.S. Magistrate Judge Susan van Keulen.
Google denied wrongdoing in agreeing to settle.
The Alphabet unit agreed in 2019 to pay $170 million in fines and change some practices to settle similar charges by the U.S. Federal Trade Commission and New York Attorney General Letitia James. Some critics viewed that accord as too lenient.
Google did not immediately respond to requests for comment on Tuesday. Lawyers for the plaintiffs did not immediately respond to similar requests.
The parents or guardians of 34 children accused Google of violating dozens of state laws by letting content providers bait children with cartoons, nursery rhymes and other content to help it collect personal information, even after the 2019 settlement.
Van Keulen dismissed claims against the content providers -including Hasbro, Mattel, Cartoon Network and DreamWorks Animation - in January, citing a lack of evidence tying them to Google's alleged data collection.
Mediation began the next month, leading to the settlement.
The proposed class covers U.S. children under 13 who watched YouTube between July 1, 2013 and April 1, 2020.
Lawyers for the plaintiffs said there could be 35 million to 45 million class members.
They said if 1% to 2% submit claims, a rate comparable to similar earlier cases, claimants could receive $30 to $60 each, before deducting legal fees and costs.
The lawyers plan to seek up to $9 million from the settlement for legal fees.
Alphabet posted net income of $62.7 billion on revenue of $186.7 billion in the first half of 2025.
The case is C.H. et al v Google LLC et al, U.S. District Court, Northern District of California, No. 19-07016.
(Reporting by Jonathan Stempel in New York; Editing by Richard Chang)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
Elite Express Holding Inc. Announces Pricing of $15.2 Million Initial Public Offering
LAGUNA HILLS, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Elite Express Holding Inc. (ETS), a last-mile delivery service provider based in California, today announced the pricing of its initial public offering of 3,800,000 shares of Class A common stock at a public offering price of $4.00 per share, for gross proceeds of approximately $15.2 million, before deducting underwriting discounts and offering expenses. In addition, ETS has granted the underwriters a 45-day option to purchase up to an additional 570,000 shares of Class A common stock at the initial public offering price. All shares of Class A common stock are being offered by ETS. The shares of Class A common stock are expected to begin trading on the Nasdaq Capital Market under the ticker symbol 'ETS' on August 21, 2025. The offering is expected to close on August 22, 2025, subject to the satisfaction of customary closing conditions. Dominari Securities LLC is acting as the representative of the underwriters for the offering, with Revere Securities acting as co-underwriter for the offering. Pacific Century Securities, LLC is acting as the advisor to ETS. A registration statement on Form S-1 (File No. 333-286965), as amended, was filed with the U.S. Securities and Exchange Commission (the 'SEC') and was declared effective on August 20, 2025. The offering is being made only by means of a prospectus forming part of the effective registration statement. A preliminary prospectus relating to the offering has been filed with the SEC. Copies of the final prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at Electronic copies of the prospectus may be obtained from the underwriter by contacting Dominari Securities LLC at 725 Fifth Avenue, 23rd Floor, New York, NY 10022, by calling (212) 393-4500 or (800) 299-7618, or by emailing info@ This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction where such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Elite Express Holding Inc. ETS is a Delaware holding company that conducts its operations through its wholly owned subsidiary, JAR Transportation Inc., based in California. ETS provides last-mile delivery services, primarily focused on transporting packages from distribution centers to end customers within defined service areas. Leveraging logistics software to support route planning, driver oversight, and regulatory compliance, ETS is committed to enhancing operational efficiency and service reliability through the use of technology-driven solutions. Forward-Looking Statements This press release contains forward-looking statements, including but not limited to statements about the anticipated timing of the offering. These statements may be identified by the use of forward-looking expressions, including, but not limited to, 'anticipate,' 'believe,' 'continue,' 'estimate,' 'expect,' 'future,' 'intend,' 'may,' 'outlook,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'will,' 'would,' and similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. These statements relate to future events, including, but not limited to, statements relating to the expected closing date of the offering and expected gross proceeds from the offering. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Important factors that could cause actual results to differ include risks related to our ability to satisfy the closing conditions related to the offering, general market and economic conditions, and those other risks as are detailed in ETS' filings with the SEC, including the registration statement on Form S-1 under the section 'Risk Factors.' ETS undertakes no obligation to update forward-looking statements except as required by law.
Globe and Mail
3 hours ago
- Globe and Mail
Genetic-Based Longevity Medicine: Enov.one Outperforms AgelessRx in Personalized Healthcare
is redefining personalized medicine by integrating genetics, labs, and wearable data into adaptive, evidence-based treatment plans, outperforming generic telehealth models like AgelessRx. With continuous monitoring, specialized practitioners, and real-time protocol adjustments, it delivers precision care that evolves with each patient's biology. Over the past decade, personalized medicine has shifted from theory to practice. Consumers increasingly expect healthcare tailored to their biology, not one-size-fits-all prescriptions. Platforms at the forefront are blending genetics, lab data, and wearable tech to deliver precision care with outperforming brands like AgelessRx to deliver superior results. Why Generic Telehealth Isn't Enough Most telehealth services still follow the same pattern: short consultations, standard prescriptions, and little follow-up. While convenient, these models leave out key variables like genetic differences, metabolic markers, and lifestyle data, all of which dramatically influence treatment outcomes. This is where differentiates itself. Unlike conventional services that rely heavily on questionnaires, it integrates multiple data sources: genetic files from 23andMe or Ancestry, lab results, and real-time data from wearables like Apple Watch or Fitbit. By combining these inputs, the platform can generate highly personalized treatment plans that adapt as patient data changes. The AgelessRx Comparison AgelessRx has carved out a reputation in longevity-focused telemedicine, but its approach resembles traditional online clinics. Protocols are largely standardized, genetic analysis isn't incorporated, and wearable integration is absent. Consultations often happen asynchronously, with limited depth of review. by contrast, emphasizes continuous monitoring and algorithm-driven adjustments. Treatment effectiveness is tracked in real time, and protocols evolve as new data is added. That feedback loop, genetics plus labs plus wearables, allows for a degree of personalization that basic telehealth platforms simply can't replicate. Evidence-Based Longevity Care One of the challenges in longevity medicine is separating science from hype. positions itself firmly in the evidence-based camp. Compounds like NAD+, glutathione, and methylcobalamin are chosen based on published studies, not wellness trends. Partner pharmacies ensure dosing precision and quality standards, with third-party testing verifying potency and purity. This scientific rigor, paired with continuous adaptation, makes stand out in a crowded field where many players focus more on marketing than measurable outcomes. The Bigger Picture The rise of platforms like reflects a broader shift in healthcare: patients no longer want generic advice or static treatment plans. They expect precision, transparency, and measurable results. While established players like AgelessRx introduced longevity care to a wider audience, next-generation platforms are pushing the field further with advanced data integration and ongoing monitoring. Modern healthcare must embrace technology rather than resist it. Electronic health records, genetic databases, and wearable devices generate unprecedented amounts of health information. Forward-thinking platforms leverage this data effectively while traditional providers struggle with basic electronic systems. Machine learning algorithms identify patterns in complex datasets that overwhelm human analysis capabilities. Genetic variants interact with environmental factors in ways that require computational power to understand fully. Manual review processes simply can't compete with sophisticated algorithmic analysis. Real-time data streams enable dynamic protocol adjustments. Static treatment plans become obsolete when continuous monitoring reveals changing health patterns. Responsive platforms adapt quickly while rigid systems maintain ineffective protocols for months. Professional Network Advantages telemedicine network includes practitioners specifically trained in longevity medicine protocols. General physicians lack specialized knowledge about anti-aging compounds and optimization strategies. This expertise gap leads to conservative prescribing and missed opportunities for meaningful health improvements. Partner pharmacies understand compounding requirements for specialized formulations. Chain pharmacies often can't fulfill customized prescriptions or handle sensitive compounds properly. Specialized fulfillment networks ensure treatment quality and reliable availability. Geographic limitations disappear with comprehensive telemedicine platforms. Rural areas lack longevity medicine specialists completely. Remote consultations provide access to expertise regardless of location while maintaining personalized attention that generic platforms can't match. Making the Switch Consumers deserve healthcare platforms that match their sophistication and health goals. Generic approaches waste time and money while delivering mediocre results. Precision medicine platforms like represent the future of optimization-focused healthcare. Getting started requires genetic testing if existing data isn't available. Recent lab work provides current health status information. Wearable devices should be connected to capture lifestyle data. The platform handles analysis and protocol development automatically. Those ready to experience genuinely personalized longevity medicine should explore comprehensive platform. Contact their team to discuss individual health goals and learn how genetic-based interventions can optimize wellness and extend healthy lifespan. The technology exists today to revolutionize personal healthcare - the question becomes whether to embrace these advances now or wait for competitors to catch up. Media Contact Company Name: Enovone, Inc. Contact Person: Enov One Email: Send Email Country: United States Website:
Globe and Mail
3 hours ago
- Globe and Mail
Rubicon Technology, Inc. to acquire Janel Group LLC
BENSENVILLE, Ill. and NEW YORK, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Rubicon Technology, Inc. (OTCQB:RBCN) ('Rubicon') and Janel Corporation (OTCQX:JANL) ('Janel Corp') today announced that they have entered into a definitive merger agreement, pursuant to which Rubicon will acquire Janel Group LLC ('Janel Group') with Janel Group becoming a wholly owned subsidiary of Rubicon and Janel Corp receiving shares of Rubicon common stock. Janel Group, based in Garden City, New York, and originally founded in 1974, is a wholly owned subsidiary of Janel Corp. Janel Group had revenues of approximately $181.3 million and operating income of approximately $8.7 million for the 12-month period ended June 30, 2025. The company is a non-asset based, full-service provider of cargo transportation logistics management services. Its management team will remain in place as part of Rubicon. The transaction allows Rubicon to acquire a profitable business and better access to capital. Janel Corp shareholders will benefit from its ownership of Rubicon. The transaction, which was approved by the Rubicon board, including its independent directors, is subject to approval by the majority of Rubicon's disinterested stockholders. Additional Transaction Details Janel Corp will sell all of the issued and outstanding equity of Janel Group to Rubicon in exchange for 7,000,000 shares of Rubicon common stock, at a value of $4.75 per share. Rubicon will assume approximately $23 million of Janel Group indebtedness and net working capital liabilities and gain access to a total of $35 million in borrowing capacity as part of a revolving credit facility under Janel Corp's existing credit line. Prior to this transaction, Janel Corp owned 1,108,000 shares of Rubicon common stock, representing approximately 46.6 percent of all outstanding Rubicon common stock. Following this transaction, Janel Corp will own approximately 86.5 percent of Rubicon's common stock. Janel Corp and Rubicon will maintain the existing governance, nomination and voting agreement requiring review and approval by Rubicon's independent directors of related party transactions between Rubicon and Janel Corp, and any of its affiliates, until such time that Janel Corp and/or its affiliates acquire more than 90 percent of Rubicon's outstanding stock. In order to protect Rubicon's ability to utilize its net operating loss carryforwards, Rubicon had previously adopted a stockholder rights plan to limit the ability of any group or person to acquire 5% or more of Rubicon's common stock (subject to certain exceptions, including acquisitions approved by its board) by any group or person. The board of Rubicon has determined that the transaction will not impair the Rubicon's net loss carryforwards. Rubicon shares will continue to be traded on the OTC market. Janel Corp Tender Offer of Rubicon Common Stock Contingent upon a successful Rubicon stockholder vote and consummation of the transaction, Janel Corp expects to make a tender offer for an additional 400,000 shares of Rubicon stock at $4.75 per share in cash upon which Janel Corp would own approximately 90.7% of Rubicon's common stock outstanding. The tender offer described in this announcement has not yet commenced. This announcement is for informational purposes only and does not constitute an offer to purchase or a solicitation of an offer to sell Rubicon's common stock. If Rubicon stockholders approve the transaction, Janel will distribute an Offer to Purchase relating to the tender offer following the consummation of the transaction, and any Rubicon stockholder who would like to participate in the tender offer should review the terms of the tender offer set forth in such Offer to Purchase when it becomes available. About Rubicon Technology, Inc. Rubicon Technology, Inc., through its wholly owned subsidiary Rubicon Technology Worldwide LLC, is an advanced materials provider specializing in monocrystalline sapphire products for optical systems and specialty electronic devices. Rubicon has expertise in sapphire products with superior quality and precision. About Janel Group LLC Janel Group LLC is a non-asset based, full-service provider of cargo transportation logistics management services, including freight forwarding via air, ocean and land-based carriers; customs brokerage services; warehousing and distribution services; trucking and other value-added logistics services. The company operates in the United States with over 25 locations and serves customers globally through its networks of international partners. Forward-looking Statements This press release contains certain statements that are, or may deemed to be, 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and that reflect management's current expectations with respect to the closing of Rubicon's acquisition of Janel Group, the benefits of the transaction for Rubicon, the continuation of agreements between Rubicon and Janel Corp following the closing of the acquisition, the tax impact of the transaction and Janel Corp's plans to commence a tender offer following approval of the transaction by Rubicon stockholders. These forward – looking statements may generally be identified using the words 'may,' 'will,' 'intends,' 'plans,' 'projects,' 'believes,' 'should,' 'expects,' 'predicts,' 'anticipates,' 'estimates,' and similar expressions or the negative of these terms or other comparable terminology. These statements are necessarily estimates reflecting management's best judgment based upon current information and involve several risks, uncertainties and assumptions. We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made, and readers are advised that various factors could affect our financial performance, including, but not limited to, those set forth in Janel Corp's Securities and Exchange Commission ('SEC') filings, which could cause Janel Corp's actual results for future periods to differ materially from those anticipated or projected in its SEC filings. While it is impossible to identify all such factors, such factors include, but are not limited to, we may fail to realize the expected benefits or strategic objectives of this transaction, or that we spend resources exploring acquisitions that are not consummated; risks associated with litigation and indemnification claims and other unforeseen claims and liabilities that may arise from an acquisition; changes in tax rates, laws or regulations and our acquired companies and subsidiaries' ability to utilize anticipated tax benefits; the impact of rising interest rates on our investments, business and operations; conflicts of interest with the minority shareholders of our business; we may not have sufficient working capital to continue operations; we may lose customers who are not obligated to long-term contracts to transact with us; instability in the financial markets; changes or developments in U.S. laws or policies (including the imposition of tariffs and any resulting counter-tariffs as well as reductions in federal government funding); competition from companies with greater financial resources and from companies that operate in areas in which we plan to expand; impacts from climate change, including the increased focus by third-parties on sustainability issues and our ability to comply therewith; competition from parties who sell their businesses to us and from professionals who cease working for us; the level of our insurance coverage, including related to product and other liability risks; each of our compliance with applicable privacy, security and data laws; risks related to the diverse platforms and geographies which host each of our management information and financial reporting systems; the Logistic business' dependence on the availability of cargo space from third parties; the impact of claims arising from transportation of freight by the carriers with which the Logistic business contracts, including an increase in premium costs; higher carrier prices may result in decreased adjusted gross profit; risks related to the classification of owner-operators in the transportation industry; recessions and other economic developments that reduce freight volumes; other events affecting the volume of international trade and international operations; risks arising from each of our ability to comply with governmental permit and licensing requirements or statutory and regulatory requirements; the impact of seasonal trends and other factors beyond our control on the Logistics business; and risks related to ownership of each of our common stock, including share price volatility, the lack of a guaranteed continued public trading market for each of our common stock, and costs related to maintaining Janel Corp's status as a public company; terrorist attacks and other acts of violence or war and, in the case of Janel Corp, such other factors that may be identified from time to time in its SEC filings. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those projected. You should not place undue reliance on any of our forward-looking statements which speak only as of the date they are made. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
